Photoaging Clinical Trial
Official title:
Effect of Autologous Platelet-rich Plasma on Photoaged Skin: A Prospective Randomized Controlled Trial (Phases A and B)
Verified date | March 2024 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to assess the safety, tolerability and effectiveness of platelet rich plasma in the treatment of photoaged skin. This study will be divided into two parts. The first part will assess the safety and tolerability of platelet rich plasma injections as compared to sterile saline injections in subjects' arm with six months follow-up. The second part will assess the effect of platelet rich plasma on the appearance of facial skin in a split face study with platelet rich plasma injections on one side of the face and sterile saline on the other. Outcomes will be recorded for twelve months.
Status | Active, not recruiting |
Enrollment | 23 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 35 Years to 60 Years |
Eligibility | Inclusion Criteria: Part 1: - Subjects of either gender (M/F), 35-60 years old. - Subjects are in good health. - Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator. Part 2: - Subjects of either gender (M/F), 35-60 years old. - Subjects are in good health. - Bilateral cheek wrinkles "in motion" with severities of = type II of Glogau photoaging classification (APPENDIX I). - Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator. - Subject requests cosmetic improvement of facial wrinkles. Exclusion Criteria: - Pregnant or lactating. - Subjects who are unable to understand the protocol or to give informed consent. - Subjects who have a self-reported history of blood or platelet disorders e.g. anemia, thrombocytopenia, coagulopathy, hypofibrinogenemia, or are on anticoagulant or antiplatelet therapy. - Subjects who have active skin disease or skin infection in treatment area. Subjects who have a history of hypertrophic scars and keloids. - Subjects who have any requirement for the use of local or systemic steroids or immunosuppressive agents. - Subject notes that he/she is HIV positive - Subjects with history of skin cancer or actinic keratosis - Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations. - Skin conditions that interfere with wrinkle assessment/treatment (excessive dermatochalasis, inability to lessen the wrinkles by physically spreading the area apart). - Excessive exposure to the sun, such as jobs requiring constant outdoor exposure. - Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, ect. Part 2: - Pregnant or lactating. - Subjects who are unable to understand the protocol or to give informed consent. - Subjects who have a history of blood or platelet disorders e.g. anemia, thrombocytopenia, coagulopathy, hypofibrinogenemia, or are on anticoagulant or anti-platelet therapy. - Subjects who have had topical or oral tretinoin, chemical peeling, botulinum toxin injection or laser and light treatment for facial rhytides or rejuvenation within past 6 months or planning to undergo treatments as described in the next 3 months. - Facial surgery in the lower 2/3 of the face or semi-permanent dermal fillers within 1 year prior to study enrollment - Subjects who have history of recurrent facial or labial herpes simplex infection. - Subjects who have active skin disease or skin infection in treatment area. - Subjects who are allergic to lidocaine or prilocaine. - Subjects who have a history of hypertrophic scars and keloids. - Subjects who have any requirement for the use of local or systemic steroids or immunosuppressive agents. - Subject notes that he/she is HIV positive - Subjects with history of skin cancer or actinic keratosis - Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations. - Skin conditions that interfere with wrinkle assessment/treatment (excessive dermatochalasis, inability to lessen the wrinkles by physically spreading the area apart). - Excessive exposure to the sun, such as jobs requiring constant outdoor exposure. - Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, ect. |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University Dermatology | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Outcome Study Part 1: Safety and Tolerability | The primary outcome measures will be the evaluation of safety and tolerability, which will be assessed by collection of adverse events throughout the feasibility study. | 2 weeks, 1 month, 3 months and 6 months | |
Primary | Primary Outcome Study Part 2: Change in Photoaging scores from Baseline at 2 weeks, 3 months, and 6 months | Photoaging scores will be recorded for each cheek by two blinded dermatologists at the treatment visit (before treatment)and during the 2 week, 3 month, and 6 month post-treatment visits. Individual scores for each variable (fine lines, mottled pigmentation, roughness, and sallowness) will be recorded by the blinded dermatologists. | Treatment visit, 2 weeks, 3 months and 6 months | |
Secondary | Secondary Outcome of Study Part 1: Histologic analysis | The secondary outcomes measures will involve the dermatopathologic review of the 2 skin biopsies taken from each subject at the one month post-treatment visit. One 3mm biopsy will be taken from the skin where the saline was injected and the other from the site of PRP injection. These will be reviewed by the dermatopathologists in the Department of Dermatology for significant histological changes, including collagen remodeling and possible reduction in photodamage. Histologic stains will include hematoxylin and eosin and Masson's trichrome. | 1 month | |
Secondary | Secondary Outcome Study Part 2: Self-Assessment | A subject self-assessment of each cheek will be performed at the 3 and 6 month follow up visits. | 3 and 6 months | |
Secondary | Secondary Outcome Study Part 2: Subject Satisfaction | A subject overall satisfaction questionnaire will be performed at the 6 month follow up visit. | 6 months | |
Secondary | Secondary Outcome Study Part 2: Rate of Adverse Events | Adverse events will be recorded at each time point, if they occur. Statitical analysis will determine the rate of any adverse events between PRP and Saline. | 2 weeks, 3 months, 6 months, 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05271136 -
A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum
|
N/A | |
Completed |
NCT05514782 -
A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum
|
N/A | |
Completed |
NCT04911374 -
An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream
|
N/A | |
Completed |
NCT04586816 -
Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging
|
N/A | |
Completed |
NCT05039723 -
Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational
|
Phase 4 | |
Not yet recruiting |
NCT05004909 -
Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream
|
N/A | |
Completed |
NCT06366503 -
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation
|
N/A | |
Completed |
NCT05027282 -
Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment
|
N/A | |
Not yet recruiting |
NCT06096649 -
The Effects of Zinc Di-(Dibutyryl Lisinate) on Skin Health and the Skin Microbiome in Photoaged Skin
|
N/A | |
Completed |
NCT03661697 -
Combination Versus Laser Treatment Only
|
N/A | |
Completed |
NCT03948945 -
Efficacy and Safety of Profile HaloTM Mixed Fractional Laser on Treating of Facial and Neck Photoaging.
|
N/A | |
Completed |
NCT06148558 -
A Twelve Week Clinical Study to Evaluate the Efficacy and Tolerability of a Sunscreen Moisturizer SPF 50+
|
N/A | |
Enrolling by invitation |
NCT06188338 -
A 56-day Clinical Study on Facial Skin Rejuvenation
|
N/A | |
Recruiting |
NCT06195605 -
Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
|
N/A | |
Not yet recruiting |
NCT04869852 -
Effects of Mango Intake on Skin Health and Gut Microbiome Changes in Postmenopausal Women
|
N/A | |
Not yet recruiting |
NCT02126644 -
The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging
|
Phase 2 | |
Unknown status |
NCT00842907 -
Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage
|
Phase 2 | |
Completed |
NCT03112863 -
Comparison of the Cosmetic Effects of Bakuchiol and Retinol
|
Early Phase 1 | |
Recruiting |
NCT05386368 -
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
|
Phase 4 | |
Recruiting |
NCT05471947 -
TCA 15% Chemical Peel for Improvement in Hand Lentigines
|
Phase 4 |